AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31615432 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cFGF23 levels
Number of subjects: 158
Study 31615432 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-specific alkaline phosphatase (BAP) levels
Number of subjects: 158
Study 31615452 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase-associated lipocalin (NGAL) measured at 6 hours after surgery
Number of subjects: 100
Study 31615452 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NGAL (PNGAL) measured at 18 hours after LT
Number of subjects: 100
Study 31615452 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase-associated lipocalin (NGAL) measured at 6 hours and 18 hours after LT
Number of subjects: 100
Study 31615452 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase-associated lipocalin (NGAL) measured at 18 hours after LT
Number of subjects: 100
Study 31615452 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase-associated lipocalin (NGAL) measured at 6 hours after LT
Number of subjects: 100
Study 31615553 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (given intravenously or orally)
Number of subjects: 0
Study 31615553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31615556 — intervention group
Group type: EXPERIMENTAL
Intervention: Floseal® treatment
Number of subjects: 7
Study 31615560 — intervention group
Group type: EXPERIMENTAL
Intervention: DuraGraft
Number of subjects: 3000
Study 31615852 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet transplantation alone (ITA)
Number of subjects: 28
Study 31615852 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet transplantation after kidney graft (IAK)
Number of subjects: 28
Study 31615852 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet transplantation (both ITA and IAK)
Number of subjects: 28
Study 31616147 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported cognitive symptoms (5-item Perceived Deficits Questionnaire score)
Number of subjects: 1159
Study 31616147 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional impairment (Sheehan Disability Scale total score)
Number of subjects: 1159
Study 31616147 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression severity (9-item Patient Health Questionnaire score)
Number of subjects: 1159
Study 31616148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once monthly (AOM 400)
Number of subjects: 229
Study 31616148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 31616309 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (MSCs)
Number of subjects: 0
Study 31616309 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stem cells (MSCs)
Number of subjects: 0
Study 31616309 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC secretion of SDF-1α
Number of subjects: 0
Study 31616348 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based instructions and EEG neurofeedback
Number of subjects: 57
Study 31616348 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index neurofeedback
Number of subjects: 57
Study 31616411 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating innate lymphoid cell subpopulations
Number of subjects: 0
Study 31617114 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 84
Study 31617114 — intervention group
Group type: COMPARATOR
Intervention: Non-operated controls (CON)
Number of subjects: 84
Study 31617211 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytosis (platelet count > 500 × 10^9/L)
Number of subjects: 156
Study 31617211 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet counts leading to bleeding complications
Number of subjects: 156
Study 31617269 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab (NTC00882999) - a BAFF inhibitor
Number of subjects: 0
Study 31617269 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept (NCT00642902) - an APRIL and BAFF inhibitor
Number of subjects: 0
Study 31617269 — intervention group
Group type: EXPERIMENTAL
Intervention: BAFF inhibition
Number of subjects: 0
Study 31617432 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib (MLN8237) combined with vorinostat
Number of subjects: 0
Study 31617910 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight or obesity
Number of subjects: 4013
Study 31617910 — intervention group
Group type: COMPARATOR
Intervention: Normal weight (control group)
Number of subjects: 4013
Study 31618131 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane plus ovarian function suppression (OFS)
Number of subjects: 4891
Study 31618131 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane plus OFS
Number of subjects: 4891
Study 31618131 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen plus OFS
Number of subjects: 4891
Study 31618131 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 4891
Study 31618297 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity pulmonary rehabilitation program (PRP)
Number of subjects: 25
Study 31618421 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly mixed meals providing variable protein (0.20-3.00 g·kg-1·d-1) as crystalline amino acids modeled after egg protein
Number of subjects: 7
Study 31618746 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial urinary [TIMP-2] × [IGFBP7] measured at baseline, 12 and 24 hours, and up to 3 days
Number of subjects: 530
Study 31618746 — intervention group
Group type: EXPERIMENTAL
Intervention: Three consecutive negative values (≤0.3 (ng/mL)2/1,000)
Number of subjects: 530
Study 31618746 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging or persistent strongly positive results (>2.0 (ng/mL)2/1,000)
Number of subjects: 530
Study 31618746 — intervention group
Group type: EXPERIMENTAL
Intervention: Test results between 0.3 and 2.0 (ng/mL)2/1,000
Number of subjects: 530
Study 31618760 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated topographic (T) method
Number of subjects: 53
Study 31618760 — intervention group
Group type: EXPERIMENTAL
Intervention: Metric (M) method
Number of subjects: 53
Study 31618760 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated topographic (T) method without 10-2
Number of subjects: 53
Study 31618760 — intervention group
Group type: EXPERIMENTAL
Intervention: Metric (M) method without 10-2
Number of subjects: 53
Study 31618760 — intervention group
Group type: COMPARATOR
Intervention: Automated topographic (T) method in healthy controls
Number of subjects: 53
Study 31618804 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous N8-GP (12.5, 25, 50, or 100 IU/kg single dose in part A; 2000 IU for patients <60 kg and 4000 IU for patients ≥60 kg daily for 3 months in part B)
Number of subjects: 50
Study 31618804 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous N8-GP
Number of subjects: 50
Study 31618841 — intervention group
Group type: EXPERIMENTAL
Intervention: High probability of pulmonary hypertension (PH) based on echocardiographic evaluation according to ESC guidelines
Number of subjects: 657
Study 31618841 — intervention group
Group type: COMPARATOR
Intervention: Low probability of pulmonary hypertension (PH) based on echocardiographic evaluation according to ESC guidelines
Number of subjects: 657
Study 31619150 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher contralateral cerebral blood flow (cCBF)
Number of subjects: 77
Study 31619150 — intervention group
Group type: COMPARATOR
Intervention: Lower contralateral cerebral blood flow (cCBF)
Number of subjects: 77
Study 31619287 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity defined by BMI (26.9% prevalence)
Number of subjects: 791
Study 31619287 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased waist circumference
Number of subjects: 791
Study 31619287 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease activity evaluated using DAS28
Number of subjects: 791
Study 31619290 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-maintenance therapy (375 mg/m2), 2 years duration after R-CVP treatment
Number of subjects: 47
Study 31619290 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-maintenance therapy
Number of subjects: 47
Study 31619433 — intervention group
Group type: COMPARATOR
Intervention: Prefrail individuals (1-2 frailty components)
Number of subjects: 7327
Study 31619433 — intervention group
Group type: COMPARATOR
Intervention: Frail individuals (≥3 frailty components)
Number of subjects: 7327
Study 31619433 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-frail individuals (0 frailty components)
Number of subjects: 7327
Study 31619433 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall associations with frailty status
Number of subjects: 7327
Study 31619435 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute surgical approach (surgery directly after the first CT at presentation)
Number of subjects: 1750
Study 31619435 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniotomy
Number of subjects: 1750
Study 31619435 — intervention group
Group type: COMPARATOR
Intervention: Expectant approach (late or no surgery)
Number of subjects: 1750
Study 31619435 — intervention group
Group type: COMPARATOR
Intervention: Decompressive craniectomy
Number of subjects: 1750
Study 31619435 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 1750
Study 31619435 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 1750
Study 31619435 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Number of subjects: 1750
Study 31619468 — intervention group
Group type: EXPERIMENTAL
Intervention: NTM-PD patients
Number of subjects: 1445
Study 31619706 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide-dexamethasone (KRd) therapy
Number of subjects: 0
Study 31619706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereblon gene variants (CRBN rs1672753)
Number of subjects: 0
Study 31619706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereblon gene variants (CRBN rs1714327)
Number of subjects: 0
Study 31620067 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study 31620067 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 0
Study 31620073 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training, details on dosage and duration not specified
Number of subjects: 0
Study 31620671 — intervention group
Group type: EXPERIMENTAL
Intervention: Groundwater iron presence
Number of subjects: 2878
Study 31620671 — intervention group
Group type: EXPERIMENTAL
Intervention: Groundwater iron presence with no vitamin C-rich or heme-iron foods consumed
Number of subjects: 2878
Study 31620671 — intervention group
Group type: EXPERIMENTAL
Intervention: Groundwater iron presence with intake of vitamin C-rich foods
Number of subjects: 2878
Study 31620671 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme-iron and vitamin C consumption
Number of subjects: 2878
Study 31620671 — intervention group
Group type: EXPERIMENTAL
Intervention: Groundwater iron presence with heme-iron or vitamin C-rich foods
Number of subjects: 2878
Study 31620672 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume supplement providing 8.2 g/d of protein
Number of subjects: 0
Study 31620787 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease activity (DA) evaluated according to SELENA-SLEDAI flare index (SFI) and revised SELENA-SLEDAI flare index (SFI-R)
Number of subjects: 336
Study 31620787 — intervention group
Group type: COMPARATOR
Intervention: Remitting patients
Number of subjects: 336
Study 31620836 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate antibiotic treatment
Number of subjects: 2960
Study 31620836 — intervention group
Group type: COMPARATOR
Intervention: Inappropriate antibiotic treatment
Number of subjects: 2960
Study 31620921 — intervention group
Group type: EXPERIMENTAL
Intervention: MIRUS™ with isoflurane, sevoflurane, or desflurane at 0.5 MAC
Number of subjects: 30
Study 31620921 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 30
Study 31621458 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune globulin subcutaneous, human - klhw 20%
Number of subjects: 0
Study 31621477 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPERA™ stent and drug-coated balloon (Passeo-18 Lux™)
Number of subjects: 20
Study 31622688 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe asthma intervention (not specified)
Number of subjects: 111
Study 31623522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting and postprandial triglyceride-rich lipoprotein particle (TRLP) concentrations and size in black women
Number of subjects: 122
Study 31623522 — intervention group
Group type: EXPERIMENTAL
Intervention: Very small TRLP concentrations
Number of subjects: 122
Study 31623657 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for men based on independent factors such as age, tobacco use, severe and permanent pain, retrosternal pain, breathing non-related pain, radiating pain, and additional symptoms.
Number of subjects: 3727
Study 31623657 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for women based on independent factors such as age ≥ 60 years, personal history of coronary artery disease, breathing non-related pain, and radiating pain.
Number of subjects: 3727
Study 31623840 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 122
Study 31623843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-processed food consumption (average 385 g/d, 24.4% of total energy intake)
Number of subjects: 11898
Study 31623843 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric substitution of ultra-processed food with unprocessed or minimally processed foods
Number of subjects: 11898
Study 31624865 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31624942 — intervention group
Group type: EXPERIMENTAL
Intervention: Third space robotic and endoscopic cooperative surgery (TS-RECS)
Number of subjects: 20
Study 31626037 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment strategies (19 different strategies applied)
Number of subjects: 40
Study 31626037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin measurement at diagnosis
Number of subjects: 40
Study 31626649 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquorice ingestion (290-370 mg/d glycyrrhizin)
Number of subjects: 42
Study 31626649 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.25 mg)
Number of subjects: 42
Study 31626649 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (400 μg)
Number of subjects: 42
Study 31626649 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquorice ingestion
Number of subjects: 42
Study 31626649 — intervention group
Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 42
Study 31627014 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic naming treatment for 12 weeks
Number of subjects: 26
Study 31627014 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 26
Study 31627014 — intervention group
Group type: COMPARATOR
Intervention: Patients with chronic aphasia pre-treatment
Number of subjects: 26
Study 31627014 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic aphasia post-treatment
Number of subjects: 26
Study 31627210 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pain (PBI > 2, N = 28)
Number of subjects: 39
Study 31627210 — intervention group
Group type: COMPARATOR
Intervention: Patients with no pain (PBI score ≦ 2, N = 11)
Number of subjects: 39
Study 31627746 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and surgery
Number of subjects: 15
Study 31627746 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 15
Study 31627746 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery arm
Number of subjects: 15
Study 31627746 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participation
Number of subjects: 15
Study 31628118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast decline in eGFR (lowest quartile of eGFR slope -4.1 ml/min per 1.73 m²)
Number of subjects: 833
Study 31628118 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline eGFR (median 73 ml/min per 1.73 m²)
Number of subjects: 833
Study 31628130 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven biomarkers (NR2, NR2 antibodies, PARK7, NDKA, UFD1, B-FABP, H-FABP)
Number of subjects: 206
Study 31628130 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical predictors of TIA/minor stroke
Number of subjects: 206
Study 31628130 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of individual biomarkers
Number of subjects: 206
Study 31628218 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical molecular imaging using Bevacizumab-800CW for evaluating circumferential resection margins (CRM) after surgical resection.
Number of subjects: 0
Study 31628489 — intervention group
Group type: EXPERIMENTAL
Intervention: White coat hypertension (office BP ≥ 135/85 mmHg and mean home BP < 130/80 mmHg)
Number of subjects: 222
Study 31628489 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypertension (pre-pregnancy hypertension with office BP ≥ 135/85 mmHg and home BP ≥ 130/80 mmHg)
Number of subjects: 222
Study 31628489 — intervention group
Group type: EXPERIMENTAL
Intervention: Normotension
Number of subjects: 222
Study 31628489 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pre-pregnancy BMI
Number of subjects: 222
Study 31628489 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher home BP
Number of subjects: 222
Study 31628489 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher prevalence of type 2 diabetes
Number of subjects: 222
Study 31628588 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived discrimination due to criminal record
Number of subjects: 743
Study 31628667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of mixed methylene blue compound
Number of subjects: 118
Study 31628986 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sentinel lymph node technique using 200 microliters of saline solution containing 37 MBq of technetium-99m nanocolloid followed by 0.5 mL of indocyanine green (ICG) injected subperitoneally.
Number of subjects: 30
Study 31628986 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sentinel lymph node technique
Number of subjects: 30
Study 31628986 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of technetium-99m nanocolloid and indocyanine green (ICG) for sentinel lymph node identification
Number of subjects: 30
Study 31629403 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Handicap Index (VHI) - Group I (40 subjects) with mild speech impairment
Number of subjects: 63
Study 31629403 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Handicap Index (VHI) - Group II (23 subjects) with moderate and profound speech deficits
Number of subjects: 63
Study 31629403 — intervention group
Group type: EXPERIMENTAL
Intervention: Frenchay Dysarthria Assessment (FDA) - Group I (40 subjects) with mild speech impairment
Number of subjects: 63
Study 31629403 — intervention group
Group type: EXPERIMENTAL
Intervention: Frenchay Dysarthria Assessment (FDA) - Group II (23 subjects) with moderate and profound speech deficits
Number of subjects: 63
Study 31629403 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment using VHI and FDA
Number of subjects: 63
Study 31629406 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-DM group (≥10 years of DM)
Number of subjects: 279
Study 31629406 — intervention group
Group type: COMPARATOR
Intervention: Non-DM group
Number of subjects: 279
Study 31629406 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-DM group (<10 years of DM)
Number of subjects: 279
Study 31629406 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DM
Number of subjects: 279
Study 31629406 — intervention group
Group type: COMPARATOR
Intervention: Patients without DM
Number of subjects: 279
Study 31629746 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated transcaval closure device (TCD)
Number of subjects: 12
Study 31630102 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound guidance
Number of subjects: 0
Study 31630102 — intervention group
Group type: COMPARATOR
Intervention: Anatomic landmark method
Number of subjects: 0
Study 31630177 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pleural adhesions
Number of subjects: 96
Study 31630177 — intervention group
Group type: EXPERIMENTAL
Intervention: VE/VCO2 slope
Number of subjects: 96
Study 31630177 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression for pleural adhesions
Number of subjects: 96
Study 31630177 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression for VE/VCO2 slope
Number of subjects: 96
Study 31630177 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC for predicting PAL
Number of subjects: 96
Study 31630414 — intervention group
Group type: EXPERIMENTAL
Intervention: TVB-2640
Number of subjects: 12
Study 31630601 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Venous Stasis Index (RVSI)
Number of subjects: 205
Study 31630601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model for composite end point
Number of subjects: 205
Study 31630886 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplatzer vascular plug (type I and type II) used in SAPE procedures
Number of subjects: 101
Study 31631693 — intervention group
Group type: EXPERIMENTAL
Intervention: Coll2-1 measurement in serum using an immunoassay
Number of subjects: 131
Study 31631693 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 131
Study 31631825 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially modifiable facilitators and barriers identified from the perspectives of patients, carers, and physicians.
Number of subjects: 0
Study 31631825 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument for the combined assessment of multiple key facilitators and barriers.
Number of subjects: 0
Study 31631825 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantification of the effect of facilitators and barriers on the duration of untreated illness (DUI).
Number of subjects: 0
Study 31631961 — intervention group
Group type: EXPERIMENTAL
Intervention: SBA-RS
Number of subjects: 470
Study 31631961 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoscopy
Number of subjects: 470